新股消息 | 汉方制药递表港交所 旗舰产品为复方黄柏液涂剂

Company Overview - Shandong Hanfang Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company engaged in the production, sales, and research and development of traditional Chinese medicine products, focusing on the treatment of skin and mucosal diseases [4] - The flagship product, Compound Huangbai Liquid, is the only approved prescription topical Chinese medicine in China, enjoying exclusive market status due to its national secondary protection status [4][5] - The company aims to diversify its product portfolio through three core strategies: advancing the research and development of new Chinese medicine products, transforming clinically validated formulations into innovative market-ready products, and commercializing acquired classic formula Chinese medicine products [4] Financial Performance - For the nine months ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately RMB 1.053 billion, RMB 992 million, and RMB 803 million, respectively [6][8] - The net profit for the same periods was approximately RMB 237 million, RMB 200 million, and RMB 145 million, respectively [6][8] - The gross profit margins for the same periods were 84.3%, 82.5%, and 84.3%, indicating a stable profitability trend [9][10] Industry Overview - The global traditional Chinese medicine market is expected to grow from RMB 1.6 trillion in 2024 to over RMB 3.4 trillion by 2034, reflecting a long-term growth trend [11] - The demand for traditional Chinese medicine is increasing globally, with applications recognized in over 180 countries, and 18 countries incorporating related content into their national healthcare systems [11] - The aging population in China is driving the demand for chronic disease management and rehabilitation, positioning traditional Chinese medicine as a suitable solution for these needs [16]